Customized assays for evaluating Rho GTPase inhibitors

We have customized biochemical, cellular and phenotypic assays for Rac1, other Rho GTPases and their genomic variants. These proprietary assays enable us to identify drug candidates for select patients whose cancers are defined by the aberration of specific Rho GTPases.

High-throughput screening

We have a unique high-throughput platform that rapidly assesses inhibitory activity of tens of thousands of compounds.

Structure-based Drug Design

We have identified allosteric binding pockets on Rho GTPase proteins to aid in structure-based drug design and guide medicinal chemistry optimization of hits from our high throughput screening.